NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...
Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of ...
"It has been a pleasure to be associated with Cumulus for the last 6 years, as founder, chair and keen supporter," said Ruth McKernan, Co-founder of Cumulus. "As my term comes to an end, I wish ...
Vigil Neuroscience, Inc. has announced its financial results for Q1 2025 and provided updates on its clinical trials. The company is on track to report the final analysis from its Phase 2 IGNITE trial ...
SAN DIEGO--(BUSINESS WIRE)--Nuvie Bio, a new clinical-stage biopharmaceutical company dedicated to addressing the most pressing unmet medical needs in migraine and related neurological diseases, ...
Modern day science tends to be highly interdisciplinary. It increasingly requires different technical topics, skills, and expertise to come together to solve complex and challenging problems and ...
Before the pandemic forced remote work, school and research to the forefront, decentralized clinical trials were probably on the horizon. Now, they’re here in earnest. This week, precision psychiatry ...
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in ...
Neuroscience is a vast field of study containing a range of narrower subfields. Each involves a spotlight on the brain and other parts of the nervous system, connecting them to one or more zones of ...
Neuroscience is a vast field of study containing a range of narrower subfields. Each involves a spotlight on the brain and other parts of the nervous system, connecting them to one or more zones of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback